Cytori Therapeutics, Inc. (CYTX) Addressing Scleroderma Hand Dysfunction through Late Stage Clinical Trial

Scleroderma is a chronic connective tissue disease that affects an estimated 300,000 people within the United States, according to the National Women’s Health Information Center. The disease is commonly associated with excessive collagen that narrows blood vessels, restricting the flow of blood to body tissues and organs and severely limiting the movement of patients’ fingers and hands. Cytori Therapeutics, Inc. (NASDAQ: CYTX) is addressing this critically underserved medical need through the continued development of ECCS-50.

ECCS-50 utilizes Cytori’s proprietary Cell Therapy™ technology, which has been shown to improve blood flow, modulate the immune system and facilitate wound repair. As a same-day treatment option using a clinical-grade preparation of the patient’s own readily available cells, the company’s technology has demonstrated a significant therapeutic impact on both acute and chronic conditions, making its scleroderma indication particularly intriguing for prospective shareholders.

In the first quarter of 2015, Cytori took a major step in the development of ECCS-50 by gaining full approval for a pivotal phase III trial for the treatment of hand dysfunction associated with scleroderma. This clinical study, which is expected to initiate enrollment in the coming weeks, headlines an extremely promising development pipeline that currently features two late-stage U.S. trials, as well as two advanced programs in international markets.

The company’s actions in recent months have focused on securing the required capital to continue development of its drug candidates. In June, the company announced a restructured debt agreement that significantly reduced its interest rate while providing repayment deferral options that will allow Cytori to more efficiently pursue development milestones.

“The restructured loan considerably reduces our near-term financing cash obligations and… significantly strengthens our balance sheet,” Tiago Giaro, chief financial officer of Cytori, stated in a news release. “We are now laser-focused on the execution of our key clinical objectives with continued emphasis on our… U.S. pivotal phase III scleroderma clinical trials.”

Moving forward, Cytori will continue to progress with the development of its leading product candidates. Look for the company to advance enrollment of its highly-anticipated scleroderma trial in the weeks to come, clearing the way for the initiation of its phase III study in the near future.

For more information, visit www.cytori.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net